Venturi Wealth Management LLC Buys 133 Shares of Insulet Co. (NASDAQ:PODD)

Venturi Wealth Management LLC lifted its stake in Insulet Co. (NASDAQ:PODD) by 633.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 154 shares of the medical instruments supplier’s stock after acquiring an additional 133 shares during the period. Venturi Wealth Management LLC’s holdings in Insulet were worth $36,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in shares of Insulet during the 2nd quarter worth $99,978,000. Baillie Gifford & Co. boosted its holdings in Insulet by 30.8% during the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after acquiring an additional 443,783 shares during the period. Canada Pension Plan Investment Board grew its position in shares of Insulet by 206.9% in the first quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier’s stock valued at $73,632,000 after purchasing an additional 289,591 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after purchasing an additional 169,506 shares during the period. Finally, First Light Asset Management LLC acquired a new position in shares of Insulet during the 1st quarter worth about $25,927,000.

Analysts Set New Price Targets

PODD has been the subject of a number of research analyst reports. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Raymond James increased their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Piper Sandler raised their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Morgan Stanley lifted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Insulet stock opened at $260.12 on Friday. The firm has a market capitalization of $18.25 billion, a P/E ratio of 44.54, a P/E/G ratio of 4.11 and a beta of 1.22. The stock has a fifty day moving average price of $237.77 and a two-hundred day moving average price of $207.47. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.